Mr. Speaker, I would like to offer the member for New Brunswick Southwest a bit of variety in terms of how he might want to rephrase his questions because it is obvious that he keeps asking the same questions. Let me provide him with a very simple answer.
His party had an opportunity in committee to examine a motion that would have dealt with an issue de facto that is increasing and extending patent protection beyond 20 years. No member of parliament in the House voted for it, but it was written in the regulations and is a mockery of our legal system.
The hon. member talks about the Patent Act as it relates to the ability of the drug manufacturing industry exclusively to claim an automatic infringement without even a shred of evidence. It has been built into the legislation. The hon. member's party had an opportunity to look at that point, open it up, and perhaps question in committee about it, but instead it defeated it.
I want to deal with what is at issue. Bill S-17 is about respecting our WTO commitments. There is no doubt the government and the minister have bravely moved ahead to ensure that the timetable is met. I compliment them for that and I believe we all agree that it should be met.
We have an obligation to look at the 1997 committee report of parliament which said in Recommendations Nos. 4 and 5 that we had to deal with regulations which were created after parliament had an opportunity to look at them. As members of parliament we are accountable to all people of Canada. Yet we have regulations which clearly and demonstrably have been shown to be more excessive than what parliament intended.
Health Canada's witnesses before the committee made very clear that the minimum extension of infringement as a result of this ridiculous automatic injunction, which exists nowhere in law and puts the reverse onus on the person applying for a new patent, creates a situation where at least 14 months is the guaranteed extension.
What is the effect on the Canadian public and the health care system? Obviously these are issues the Conservative Party and that member choose to ignore. We on this side of the House recognize the international obligations but at the same time want to make sure we have laws and regulations consistent with public expectation.
In an earlier speech the same hon. member commented on the west island of Montreal and other places across Canada that are doing very well. If the hon. member really cared about understanding where we are relative to fantasyland, he would have asked a question that was raised in committee: Why is it that Canada is now recording a $4 billion trade deficit when it comes to pharmaceuticals when it was only at $1 billion in 1993? Is this his vaunted research and development?
Let us talk about research and development. We now find that a good deal of the $900 million is nothing more than advertising. Does the hon. member not find a problem with trying to tell Canadians on the one hand that they are getting lots of research and development when it is advertising to continue the opportunity of these companies to make a bit more money at the same time?
We have the highest prices for drugs in the world. The hon. member did not want to talk the question of relativity to other countries. It strikes me that we have a drug regime in which Canadians are paying among the highest prices in the world. Seventy per cent of the people in my province do not have adequate drug protection. They are people from my age all the way up to age 64. If these issues could be raised perhaps there would be some impetus to create an opportunity for us to deal with our health care system.
I hope hon. members on the other side are listening. The government and this party are. I wish they would.